Oct. 20 at 1:00 PM
This is not investment advice because
$SNDX has a 10/25/2025 PDUFA date (this week) for its Revuforj in mNPM1 leukemias. Should the FDA issue SNDX a CRL SNDX's share price could meaningfully fall.
Yes we post data on SNDX more than any other commercial-stage oncology focused bio. This is because traditional valuation metrics suggest SNDX trades at material discounts versus peers.
Attached is a list of the FY2029 revenue multiple of SNDX versus every commercial-stage non-oncology focused peer with a market cap between
$1.X &
$2.5B sorted by FY29 multiple (where more than 1 analyst provides a FY29 estimate).
Note SNDX trades at the lowest multiple of FY2029 analyst estimates versus this peer group. We therefore suspect, SHOULD THE FDA APPROVE SNDX's SUBMISSION, SNDX may be undervalued.
The only non-oncology focused peer excluded was
$HRMY which trades at a lower FY29 multiple, we assume, due to an imminent patent cliff.
Even
$SRPT trades at a higher multiple.
$ARDX $BCRX